Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

CDC Science Clips
COVID-10 GPH

Last data update: Jan 13, 2025. (Total: 48570 publications since 2009)
(Author names in bold with hyperlink are CDC authors)
Filtered By:
Order By:
Records 1-2 (of 2 Records)
Query Trace: Taylor Walker A[original query]
Notes from the field: Early identification of the SARS-CoV-2 Omicron BA.2.86 variant by the traveler-based genomic surveillance program - Dulles International Airport, August 2023
Bart SM , Rothstein AP , Philipson CW , Smith TC , Simen BB , Tamin A , Atherton LJ , Harcourt JL , Taylor Walker A , Payne DC , Ernst ET , Morfino RC , Ruskey I , Friedman CR .
MMWR Morb Mortal Wkly Rep 2023 72 (43) 1168-1169 type type

During August 13–14, 2023, a new SARS-CoV-2 Omicron subvariant with a large number of mutations compared with previously circulating BA.2 variants (>30 amino acid differences in its spike protein) was identified by genomic sequencing in Denmark and Israel and subsequently designated BA.2.86 (1,2). Given near-simultaneous detections in multiple countries, including the United States, further information was needed regarding geographic spread of BA.2.86. Since January 2022, submissions to SARS-CoV-2 sequence repositories have declined by 95%,* substantially decreasing global capacity to monitor new variants. To fill gaps in global surveillance, CDC’s Traveler-based Genomic Surveillance (TGS) program was developed to provide early warning of new variants entering the United States by collecting samples from arriving international travelers (3).
Acquisition and long-term carriage of multidrug-resistant organisms in US international travelers
Worby CJ , Earl AM , Turbett SE , Becker M , Rao SR , Oliver E , Taylor Walker A , Walters M , Kelly P , Leung DT , Knouse M , Hagmann SHF , Ryan ET , LaRocque RC .
Open Forum Infect Dis 2020 7 (12) ofaa543

We performed prospective screening of stool for multidrug-resistant organisms from 608 US international travelers and identified an acquisition rate of 38% following travel. Carriage rates remained significantly elevated for at least 6 months post-travel. Travel-related diarrhea was a risk factor for acquisition, as well as for long-term carriage upon return.
TOP